10X Genomics Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of 10X Genomics Inc (TXG). It shows which part of the business is growing — and which one is holding it back.
Remaining performance obligations
Remaining performance obligations are the part of the business already sold but not yet delivered and therefore not yet booked as revenue. In subscription and project businesses it points the way earlier than revenue does.
| As of | Remaining performance obligations |
|---|---|
| Q4 2025 | $34.4M |
| Q3 2025 | $33.0M |
| Q2 2025 | $32.7M |
| Q1 2025 | $33.5M |
| Q4 2024 | $33.2M |
| Q3 2024 | $30.1M |
| Q2 2024 | $27.8M |
| Q1 2024 | $24.1M |
Data as of: August 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.